
Survodutide demonstrated cardiovascular safety vs placebo in the phase 3 SYNCHRONIZE-CVOT trial, with improvements in weight and cardiometabolic risk factors.
Video: Obesity expert Dr Louis Aronne outlines the role of medication in obesity treatment and says primary care is absolutely the place to begin.






